Revvity, Inc., formerly PerkinElmer, Inc., is a global enterprise headquartered in Waltham, Massachusetts, founded in 1937. With over 11,000 employees across 190 countries, the company operates through two main segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides advanced instrumentation, reagents, informatics, and software for life sciences research, including detection and imaging technologies, contract research, and laboratory services. It also supplies analytical tools for environmental health (air, water, soil), agriculture, food safety, and industrial markets (chemicals, semiconductors, electronics, energy, and polymers). The Diagnostics segment focuses on early detection and screening of genetic disorders and infectious diseases, offering instruments, reagents, and software for applications like newborn screening, prenatal testing, and oncology. Revvity leverages next-generation sequencing and protein-coupled receptor technologies to support genomic workflows. The company serves pharmaceutical and biotech firms, academic institutions, public health agencies, and healthcare providers. Financially, Revvity reported approximately $3 billion in revenue with a market cap around $12.8 billion, emphasizing R&D (7.4% of revenue) and maintaining a gross margin of 52.1%. Under CEO Prahlad Singh, the company continues to innovate, launching AI-powered SaaS platforms like Revvity Signals for data-driven research. With a commitment to expanding human potential, Revvity aims to revolutionize healthcare through translational multi-omics and biomarker technologies.
